Adjuvant therapy with trastuzumab emtansine has shown improved outcomes. New research findings are summarized in a short video.

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...

Trastuzumab emtansine (T-DM1) demonstrates sustained improvement in invasive disease-free survival and reduced the risk for death in human epidermal growth factor receptor 2 (HER2)-positive breast ...

Adjuvant ado-trastuzumab emtansine improved survival compared with trastuzumab for early HER2-positive breast cancer. Long-term follow-up showed a continued DFS benefit with ado-trastuzumab ...